Androgen deprivation therapy potentiates cardiovascular morbidity and mortality, which is the most common cause of non-cancer-related death in patients with prostate cancer. Whether the mode of testosterone suppression affects the risk of cardiovascular adverse events is unclear, especially as the 2021 PRONOUNCE trial — which aimed to compare the cardiovascular risks of gonadotropin-releasing hormone (GnRH) antagonists with GnRH agonists — was prematurely terminated.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Huggins, C. & Hodges, C. V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J. Urol. 168, 9–12 (2002).
Blackard, C. E. The Veterans’ Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review. Cancer Chemother. Rep. 59, 225–227 (1975).
Schally, A. V., Coy, D. H. & Arimura, A. LH-RH agonists and antagonists. Int. J. Gynecol. Obstet. 18, 318–324 (1980).
Trachtenberg, J. et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J. Urol. 167, 1670–1674 (2002).
Levine, G. N. et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk. Circulation 121, 833–840 (2010).
Nguyen, P. L. et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306, 2359–2366 (2011).
Albertsen, P. C. et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur. Urol. 65, 565–573 (2014).
Lopes, R. D. et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation 144, 1295–1307 (2021).
Shore, N. D. et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N. Engl. J. Med. 382, 2187–2196 (2020).
Sun, L. et al. Assessment and management of cardiovascular risk factors among US veterans with prostate cancer. JAMA Netw. Open 4, e210070 (2021).
P.R. declares research grant support from Ferring Pharmaceuticals. K.A. declares no competing interests.
Rights and permissions
About this article
Cite this article
Atalar, K., Rajan, P. Understanding and managing the cardiovascular risks of androgen deprivation therapy for prostate cancer. Nat Rev Urol 20, 3–4 (2023). https://doi.org/10.1038/s41585-022-00671-5